Equities

Semler Scientific Inc

Semler Scientific Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)66.43
  • Today's Change7.16 / 12.08%
  • Shares traded3.29m
  • 1 Year change+79.88%
  • Beta1.0925
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Semler Scientific Inc grew revenues 20.28% from 56.69m to 68.18m while net income improved 43.69% from 14.33m to 20.58m.
Gross margin88.05%
Net profit margin27.00%
Operating margin33.22%
Return on assets18.54%
Return on equity20.39%
Return on investment20.37%
More ▼

Cash flow in USDView more

In 2023, Semler Scientific Inc increased its cash reserves by 149.12%, or 34.32m. The company earned 21.33m from its operations for a Cash Flow Margin of 31.28%. In addition the company generated 18.40m cash from investing, though they paid out 5.41m more in financing than they received.
Cash flow per share2.13
Price/Cash flow per share26.02
Book value per share11.99
Tangible book value per share2.93
More ▼

Balance sheet in USDView more

Semler Scientific Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 57.20m.
Current ratio3.14
Quick ratio3.09
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 47.00%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)31.99
EPS (TTM) vs
TTM 1 year ago
-17.64
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.